Non Small Cell Lung Cancer - sintilimab + fruquintinib - PD-L1 expression

Association details:

Biomarker:	PD-L1 expression
Cancer:	Non Small Cell Lung Cancer
Drug:	Tyvyt (sintilimab) (PD1 inhibitor) + Fruzaqla (fruquintinib) (VEGFR inhibitor)
Direction:	Sensitive

Evidence:

Evidence Level:

Sensitive: C3 – Early Trials

Source:

ESMO Asia 2023

Title:

496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study

Published date:

11/27/2023

Excerpt:

15mo-PFS rate was 55.9% (95%CI: 24.0%, 79.0%), and 18mo-OS rate was 60.6% (95%CI: 29.4%, 81.4%)….F plus S showed a promising antitumor activity and manageable toxicity for advanced NSCLC with PD-L1-positive status. This study might represent a potential treatment option for these pts, especially for pts who can not tolerate chemotherapy.